• Home
  • NEW DAY MEDICINE
  • 2 (26) 2019
  • 36 -2 (26/1) 2019 — B.T. Daminov, D.A. Egamberdieva — THE STUDY EFFICACY AND SAFETY OF LAW MOLECULAR IRON DEXTRAN (III) DURING THE CORRECTION OF RENAL ANEMIA WITH EPOIETIN BETA

36 -2 (26/1) 2019 — B.T. Daminov, D.A. Egamberdieva — THE STUDY EFFICACY AND SAFETY OF LAW MOLECULAR IRON DEXTRAN (III) DURING THE CORRECTION OF RENAL ANEMIA WITH EPOIETIN BETA

THE STUDY EFFICACY AND SAFETY OF LAW MOLECULAR IRON DEXTRAN (III) DURING THE CORRECTION OF RENAL ANEMIA WITH EPOIETIN BETA

B.T. Daminov, Tashkent Pediatric Medical Institute.

D.A. Egamberdieva Tashkent Pediatric Medical Institute.

Resume

Due to the fact, that endothelial dysfunction is multifaced, it seems reasonable to study such a markers of endothelial dysfunction as inflammation and oxidative stress, it will permit the better prediction of cardiovascular risk factors in patients with CKD. The study of the markers responsible to the inflammatory, anti-inflammatory, metabolic effects in the organism demonstrated that such indices as IL-6, CRP and fibrinogen had the relevant correlation with the gravity of atherosclerosis in CKD patients.

Keywords: chronic kidney disease, systemic inflammation, glomerular filtration rate, Doppler ultrasonography of carotid arteries.

First page

140

Last page

143

For citation: B.T. Daminov, D.A. Egamberdieva The study efficacy and safety of law molecular iron dextran (iii) during the correction of renal anemia with epoietin beta//New Day in Medicine 2(26) 2019 140-143 https://cutt.ly/mbYZeSn

List of References

  1. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J. i SAR. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research. //Clinical Cardiology and Epidemiology and Prevention. Circulation. 2003;110(12):1514-1517.
  2. Nelson K, Thethi I, Cunanan J, Hoppensteadt D, Bajwa R, Fareed J, Bansal V. Upregulation of surogate markers of inflamation and thrombogenesis in patients with ESRD: pathophysiologic and therapeutic implications. //Clin Appl Thromb Hemost. 2011;17(3):302-304.
  3. Chaykovska L, Tsuprykov O, Hocher B. Biomarkers for the prediction of mortality and morbidity in patients with renal replasement therapy. //Clin Lab. 2011; 57(7-8):455-467.
  4. Wattanakit K, Cushman M. Chronic Kidney Disease and Venous Thromboembolism: Epidemiologia and Mechanisms. //Curr Opin Pulm Med. 2009; 15(5):408-412.
  5. Levy AS, Eckardt KU, Tsukamoto Y, Knoyan G. Definition and classification of chronic kidney disease; A position statement from Kidney Disease; //Improving Global Outcomes (KDIGO) Kidney Int. 2005;67(6):2089-2100.
  6. Upadhyay A, Larson MG, Guo CY, Vasan RS, LipinskaI, ODonnell CJ, Kathiresan S, Meigs JB, Keaney JF, Rong J, Benjamin EJ, Fox C. Inflamation, kidney funkcion and albuminuria in the Framingham Offspring cohort. //Nephrol Dial Transplant. 2011;26(3):920-926.
  7. Vidt DG. Inflammation in renal disease. //Am J Cardiol. 2006; 97:20A-27A.
  8. Recio-Mayoral A, Banerjee D, Streather C, Kaski JC. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease-a cross-sectional study of predialysis, dialysis and kidney­transplantation patients. //Atherosclerosis. 2011;216(2):446-451.
  9. Annuk M, Soveri I, Zilmer M, Lind L, Hulthe J, Fellstrom B. Endothelial function, CRP and oxidative stress in chronic kidney disease. //J Nephrol. 2005;18(6):721-726.
  10. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M, Periera BG, Feldman HI, Kusek JW, Joffe MM, Raj DS. Association betwen albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIS. //Clin J Am Nephrol. 2012;7(12):1938-1946.
  11. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ. The relationship between non- tradicional risk factors and autcomes in individuals with stage 3-4 CKD. //Am J Kidney Dis. 2008; 51:212-223.
  12. Keller C, Katz R, Sarnak MJ, Fried LF, Kestenbaum B, Cushman M, Shlipak MG. Inflammatory biomarkers and decline in kidney function in the elderly: Cardiovascular Helth Stady. //Nephrol Dial Transplant. 2010; 25:119-124.
  13. Robert A, Olmer M, Sampol J, Gugliotta JE, Casanova P. Clinical correlation betwen hypercoagulability and thrombo-embolic phenomena. //J Lab Clin Med. 1987; 31:830-835.
  14. Wolfgang Koenig, Natalie Khuseyinova, Jens Baumert, Barbara Thorand, Hannelore Loewel, Lloyd Chambless, Christa Meisinger, Andrea Schneider, Stephan Martin, Hubert Kolb, and Christian Herder. Increased Concentrations of C – reactive protein and IL-6 but not IL-18 Are Independently Associated with Incident Coronary Events in Middle-Aged Men and Women/ Results from the MONICA/KORA Augsburg Case­Cohort Study, 1984-2002. //Arterioscler Thromb Vasc Biol. 2006; 26:2745-2751. https://www.ahajournals.org/toc/atvb/26/12


file

download